See how AbbVie Inc. and Chevron Corporation differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Chevron Corporation is an integrated energy company engaged in worldwide oil and gas exploration, production, and refining. It is the second-largest oil company in the United States, reporting 2025 net oil-equivalent production of 3.7 million barrels per day, including 8.5 billion cubic feet of natural gas per day and 2.3 million barrels of liquids per day. The company produces energy across North America, South America, Europe, Africa, Asia, and Australia. Chevron’s refining network is concentrated in the United States and Asia, with total global refining capacity of 1.8 million barrels per day at year-end 2025. At the end of 2025, net proved reserves totaled 10.6 billion barrels of oil equivalent, including 5.7 billion barrels of liquids and 29.2 trillion cubic feet of natural gas.